Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries

Osteoporosis International

Volumn 25, Issue 8, 2014, Pages 2109-2116

  Wang, Z ^a   Ward, M M ^a   Chan, L ^b   Bhattacharyya, T ^a,c  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NONE   (United States)

Author keywords

Atypical femur fracture; Bisphosphonates; Fracture; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; FEMUR INTERTROCHANTERIC FRACTURE; FEMUR NECK FRACTURE; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICARE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; CHEMICALLY INDUCED; COMPLICATION; DRUG ADMINISTRATION; FEMORAL FRACTURES; FEMORAL NECK FRACTURES; HIP FRACTURES; INCIDENCE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMORAL FRACTURES; FEMORAL NECK FRACTURES; HIP FRACTURES; HUMANS; INCIDENCE; MEDICARE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84904423383     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2738-x     Document Type: Article

References (27)

1. Gedmintas L, Solomon DH, Kim SC (2013) Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 28(8):1729-1737
2. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25(11):2267-2294
3. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res 29(1):1-23, Epub 2013/05/29
4. Schilcher J, Koeppen V, Ranstam J, Skripitz R, Michaelsson K, Aspenberg P (2013) Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone 52(1):389-392
5. Wang Z, Bhattacharyya T (2011) Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 26(3):553-560
6. Ng AC, Drake MT, Clarke BL, Sems SA, Atkinson EJ, Achenbach SJ et al (2012) Trends in subtrochanteric, diaphyseal, and distal femur fractures, 1984-2007. Osteoporos Int 23(6):1721-1726
7. Yoon BH, Lee YK, Kim SC, Kim SH, Ha YC, Koo KH (2013) Epidemiology of proximal femoral fractures in South Korea. Arch Osteoporos 8(1-2):157
8. Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE (2012) Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 172(12):930-936
9. Feldstein AC, Black D, Perrin N, Rosales AG, Friess D, Boardman D et al (2012) Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 27(5):977-986
10. Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO et al (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27(12):2544-2550
11. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC et al (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. Jama 305(8):783-789
12. Abrahamsen B, Eiken P, Eastell R (2010) Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 95(12):5258-5265
13. Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24(6):1095-1102
14. Hsiao FY, Huang WF, Chen YM, Wen YW, Kao YH, Chen LK et al (2011) Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women. Clin Ther 33(11):1659-1667
15. Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH (2011) Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res 26(5):993-1001
16. Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L (2011) Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int 22(3):993-1001
17. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B et al (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20(8):1353-1362
18. Girgis CM, Sher D, Seibel MJ (2010) Atypical femoral fractures and bisphosphonate use. N Engl J Med 362(19):1848-1849
19. Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE (2011) Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 48(5):966-971
20. Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364(18):1728-1737
21. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E (2008) Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 23(9):1435-1441
22. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013-1022 (Pubitemid 44175011)
23. Pazianas M, Abrahamsen B, Wang Y, Russell RG (2012) Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US Market Scan claims databases. Osteoporos Int 23(12):2873-2884
24. Fay MP, Feuer EJ (1997) A semi-parametric estimate of extra-Poisson variation for vital rates. Stat Med 16(21):2389-2401 (Pubitemid 27472713)
25. Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16(3):1141-1154
26. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S (2011) A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 64(7):749-759
27. Narongroeknawin P, Patkar NM, Shakoory B, Jain A, Curtis JR, Delzell E et al (2012) Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data. J Clin Densitom 15(1):92-102